Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.
OBJECTIVE
To establish a method to detect the expression of the tumor specific growth factor TSGF, CA242 and CA19-9 in serum and evaluate their value in diagnosis of pancreatic cancer.


METHODS
ELISA and Biochemical colorimetric assay were used to detect the serum content of TSGF, CA242 and CA19-9 in 200 normal cases, 52 pancreatitis patients and 96 pancreatic cancer patients.


RESULTS
The positive likelihood ratios of TSGF, CA242 and CA19-9 were 5.4, 12.6 and 6.3, respectively, and their negative likelihood ratios were 0.10, 0.19 and 0.17, respectively. With single tumor marker diagnosed pancreatic cancer, the highest sensitivity and specificity of TSGF were 91.6% and 93.5%. In combined test with 3 markers, when all of them were positive, the sensitivity changed to 77.0% and the specificity and the positive predictive value were 100%. The levels of TSGF and CA242 were significantly higher in the patients with pancreatic cancer of head than those in the patients with pancreatic cancer of body, tail and whole pancreas, but the expression of CA19-9 had no correlation with the positions of the pancreatic cancer. The sensitivity of TSGF, CA242 and CA19-9 was increased with the progress in stages of pancreatic cancer. In stage I, the sensitivity of TSGF was markedly higher than CA242 and CA19-9.


CONCLUSIONS
The combined use of TSGF, CA242 and CA19-9 expressions can elevate the specificity for pancreatic cancer diagnosis. And it shows that it plays an important role to differentiate positions and tissue typing. It is a forepart diagnosis for the pancreatic cancer by combination checking. There is very important correlation between the three markers and the pancreatic cancer.
Jiang
Jing-Ting
JT
Department of Tumor Biological Treatment, Third Affiliated Hospital of Suzhou University, Changzhou 213003, Jiangsu Province, China. jitnew@163.com
Wu
Chang-Ping
CP
Deng
Hai-Feng
HF
Lu
Ming-Yang
MY
Wu
Jun
J
Zhang
Hong-Yu
HY
Sun
Wen-Hui
WH
Ji
Mei
M
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood*; D042241:Early Diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000473:pathology*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity
D015295:Antigens, Tumor-Associated, Carbohydrate; C074601:CA 242 antigen; D018395:CA-19-9 Antigen